Pan-TB Treatment
Designed to work without requiring prior rifampicin susceptibility testing.
Project annexure / Multi-country trial
PanTB-HM
Developing shorter, safer TB treatment for all patients.
PanTB-HM is a multi-country Phase 2c clinical trial investigating a novel pan-TB treatment regimen designed to work regardless of rifampicin resistance status. The study combines antimicrobial treatment and host-directed therapy approaches aimed at improving cure, preserving lung health and simplifying TB treatment globally.
Study Overview
Investigating a new treatment approach designed to simplify TB care and improve long-term patient outcomes.
Focus Areas
Shorter Treatment
Investigating treatment approaches that may reduce treatment duration.
Host-Directed Therapy
Exploring whether NAC can help protect the lungs and liver during treatment.
Lung Health
Looking beyond cure to support long-term patient health outcomes.
The Regimen
SBPN Regimen
Sutezolid
Bedaquiline
Pretomanid
N-acetylcysteine (NAC)
What Makes This Study Different
Combining evidence, innovation and implementation.
Pan-TB Strategy
Designed for treatment regardless of rifampicin resistance status.
Host-Directed Therapy
Investigating whether NAC may help reduce treatment-related damage and support recovery.
Improved Drug Safety
Evaluating sutezolid as a potentially safer treatment option.
Long-Term Outcomes
Exploring how treatment impacts lung health beyond microbiological cure.
Why This Study Matters
Current TB treatment regimens are often long, complex and difficult to tolerate, particularly for people living with drug-resistant TB.
Even after cure, many patients experience long-term lung damage that affects quality of life and overall health.
PanTB-HM is investigating whether a shorter, simpler treatment approach can improve outcomes while helping preserve long-term lung function.
Where We Work
Countries, provinces and sites in the programme.
| Country / Province | Sites / details |
|---|---|
| South Africa | Tembisa, Helen Joseph Hospital, Durban, George, Rustenburg |
| Mozambique | CISPOC – Maputo |
| Tanzania | Mbeya Medical Research Centre |
Latest Updates
Update category
PanTB-HM AGM Marks Five Years of Progress
Update category
World TB Month Site Tour
Update category
Recruitment Launch Updates
Consortium Partners
Organisations working together across the programme.
Aurum Institute / LMU MunichINS Mozambique / RadboudumcWits CHRU / Stellenbosch UniversityNIMR Tanzania / TB AllianceTASK Eden / Sequella Inc
Supported by
PanTB-HM [RIA2019AMR-2647] forms part of the EDCTP2 Programme supported by the European Union.
Contact the Study Team
dmudzengi@auruminstitute.org · +27 10 590 1388